Cargando…
Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
Ruxolitinib is the only therapy with an approved indication for myelofibrosis (MF), a myeloproliferative neoplasm associated with progressive bone marrow fibrosis and extramedullary hematopoiesis. Although the pivotal phase 3 COMFORT studies included only patients with intermediate-2 or high-risk MF...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975083/ https://www.ncbi.nlm.nih.gov/pubmed/27463690 http://dx.doi.org/10.1080/10428194.2016.1195501 |